China Bio Health Group

China Bio Health Group, Inc. is a healthcare company that historically focused on the development and commercialization of biotechnology and pharmaceutical products within the People's Republic of China. The company's primary product line centered on recombinant human epidermal growth factor (rhEGF), marketed for the treatment of various skin conditions including wounds, burns, and ulcers. Beyond its biotech interests, the firm also engaged in the distribution of traditional Chinese medicines and health supplements through its subsidiaries. Although it was publicly traded on the OTC market, the company has since become inactive, with no significant recent operational or clinical developments reported in several years.